Eisai revealed its single-agent Phase III trial of eribulin mesylate showed improved overall survival in patients with locally recurrent or metastatic breast cancer.

The phase III Embrace study compared treatment using eribulin with Treatment of Physician’s Choice (TPC) in heavily pre-treated metastatic breast cancer patients.

The trial showed that patients who received eribulin survived a median of 2.5 months longer than patients who received TPC.

The open-label, randomised, multi-centre Embrace study examined 762 patients with metastatic breast cancer, previously treated with at least two and a maximum of five prior chemotherapies.

TPC is a single-agent chemotherapy, hormonal treatment or biological therapy approved for the treatment of cancer.

Patients administered with eribulin showed adverse effects such as fatigue (53.7%), low white blood cell counts (51.7%), hair loss (44.5%), and numbness and tingling in different parts of the body (34.6%).